Select Page

EpiVax says Novozymes Collaboration has $3bn Potential

by: Gareth Macdonald

EpiVax says combining its immune ‘off switch’ drugs with Novozymes’ half-life boosting Albufuse platform could deliver a $3bn (€2.2bn) section of the autoimmune disease market.

Full Article in in-Pharma Technologist.com – http://bit.ly/EpiVaxNZinterPR